Jingsong Zhang

Jingsong Zhang

H. Lee Moffitt Cancer Center & Research Institute - Tampa / United States
Others
AD Scientific Index ID: 4920031
person_outline Jingsong Zhang's MOST POPULAR ARTICLES
1-) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label studyT Powles, PH O\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Donnell, C Massard, HT Arkenau, TW Friedlander, ...JAMA oncology 3 (9), e172411-e172411, 20177772017
2-) Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alterationW Abida, A Patnaik, D Campbell, J Shapiro, AH Bryce, R McDermott, ...Journal of Clinical Oncology 38 (32), 3763, 20204392020
3-) Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancerJ Zhang, JJ Cunningham, JS Brown, RA GatenbyNature communications 8 (1), 1-9, 20174142017
4-) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...The Lancet Oncology 21 (12), 1574-1588, 20204352020
5-) Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 …W Abida, D Campbell, A Patnaik, JD Shapiro, B Sautois, NJ Vogelzang, ...Clinical Cancer Research 26 (11), 2487-2496, 20203642020